Scienza e Tecnologia
One-Stop CLIA Solution with Open Systems and Resources Makes Evolution to Emerging World Healthcare Systems
The One-Stop CLIA Solution brings in the COVID-19 Neutralizing Antibody (NAb) Test, one of the indispensable tools to assess immune response after vaccination. This product can achieve high-throughput quantitative detection with a high correlation to FDA EUA NAb Test and the gold standard plaque reduction neutralization test. Alongside the NAb test, the COVID-19 Ag Selt Test was also launched for disease containing.
Fapon Biotech products and services are highly integrated to promote synergic resources and shared values to different healthcare systems. With an outstanding track record of helping IVD partners in product development and localization, the cooperation through the One-Stop CLIA Solution will assist partners in completing transformations, lowering operation costs, and driving innovations into businesses.
Fapon Biotech was founded in 2001. Guided by the mission of "Enable Disease Identification Earlier, More Accurate, Convenient and Affordable", the company focuses on the future needs of biotechnology developments and provides global diagnostic companies with high-performance IVD reagent raw materials, such as antigens, antibodies, and enzymes, as well as one-stop solutions with instrument and reagent services.
Cathy Gan
market@fapon.com
Photo - https://mma.prnewswire.com/media/1496064/1.jpg